Merck
Merck develops and produces medicines, vaccines, biologic therapies and animal health products.
Launch date
Employees
Market cap
AUD451.5b
Enterprise valuation
AUD492.3b (Public information from Sep 2024)
Share price
$118.64 MRK
Kenilworth Illinois (HQ)
Corporate Venture Fund: MRL Ventures, MSD Global Health Innovation Fund
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 48.0b | 48.7b | 59.3b | 60.1b | 64.2b | 68.5b | 72.7b |
| % growth | 2 % | 1 % | 22 % | 1 % | 7 % | 7 % | 6 % |
| EBITDA | 9.1b | 13.9b | 18.6b | 7.5b | 28.1b | 32.6b | 34.9b |
| % EBITDA margin | 19 % | 28 % | 31 % | 13 % | 44 % | 48 % | 48 % |
| Profit | 7.1b | 13.0b | 14.5b | 365m | 19.0b | 22.9b | 25.7b |
| % profit margin | 15 % | 27 % | 24 % | 1 % | 30 % | 33 % | 35 % |
| EV / revenue | 4.8x | 4.5x | 5.0x | 5.1x | 5.0x | 4.5x | 4.0x |
| EV / EBITDA | 25.5x | 15.8x | 16.1x | 40.4x | 11.4x | 9.4x | 8.4x |
| R&D budget | 13.6b | 12.2b | 13.5b | 30.5b | - | - | - |
| R&D % of revenue | 28 % | 25 % | 23 % | 51 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | N/A | Grant | |
| N/A | $1.5m | Grant | |
| N/A | $600k | Post IPO Equity | |
$356m | Grant | ||
* | $3.5m | Post IPO Equity | |
* | $231k | Post IPO Equity | |
| Total Funding | AUD552m | ||
Related Content
Recent News about Merck
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
ACQUISITION by Pfizer Mar 2023
exited
ACQUISITION by Atlas Neon Parent Feb 2024
exited
ACQUISITION by Merck May 2019
ACQUISITION by Merck Sep 2021
ACQUISITION by Merck Jun 2016
